Artiva Biotherapeutics Common StockNASDAQ: ARTV

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Next earnings report:

29 November 2024

Last dividends:

N/A

Next dividends:

N/A
$192.71 M
-30%vs. 3y high
54%vs. sector
-vs. 3y high
-vs. sector
-30%vs. 3y high
38%vs. sector
-30%vs. 3y high
94%vs. sector

Price

regular market | Wed, 20 Nov 2024 14:30:00 GMT
$10.96-$0.34(-3.01%)

Dividend

No data over the past 3 years
$0.00-$17.47 M

Analysts recommendations

Institutional Ownership

Included in screeners

No data

ARTV Latest News

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
globenewswire.com12 November 2024 Sentiment: POSITIVE

Expanded Board of Directors with appointment of Dr. Alison Moore bringing cell therapy and manufacturing expertise to advance AlloNK® in autoimmune diseases

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference
globenewswire.com11 November 2024 Sentiment: POSITIVE

SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 3:30 p.m. GMT, in London, UK.

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
globenewswire.com22 October 2024 Sentiment: POSITIVE

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors.

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
globenewswire.com29 August 2024 Sentiment: POSITIVE

Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring multiple autoimmune indications Treated first patient in Artiva sponsored Phase 1/1b trial in patients with class III or IV lupus nephritis (LN) and expanded trial to include patients with systemic lupus erythematosus (SLE) without kidney involvement SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent progress. “Artiva is at an inflection point as we advance AlloNK® in clinical development across multiple autoimmune indications and transition to a publicly traded company,” said Fred Aslan, M.D.

This Biotech IPO Stock Aims to Seize a Multibillion-Dollar Market with Its Innovative Treatment
fool.com29 August 2024 Sentiment: POSITIVE

Artiva has two-bagger potential in the eyes of multiple Wall Street analysts. Its cell therapies could provide a much more efficient treatment of autoimmune diseases.

Artiva Biotherapeutics' Investigational Scalable Cell Therapies For Autoimmune Disorders, Analyst Initiate With Bullish Pitch
benzinga.com13 August 2024 Sentiment: POSITIVE

In July, Artiva Biotherapeutics, Inc. ARTV priced its upsized initial public offering of 13.92 million shares at $12.00 per share, with gross proceeds of approximately $167.0 million.

Insider Buying in These 2 IPOs Is Huge, Plus Financial CEOs Pick Up Shares
247wallst.com28 July 2024 Sentiment: POSITIVE

24/7 Wall St. Insights In the past week or so, initial public offerings at a biotech and an investment management firm attracted huge insider buying.

What type of business is Artiva Biotherapeutics Common Stock?

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

What sector is Artiva Biotherapeutics Common Stock in?

Artiva Biotherapeutics Common Stock is in the Healthcare sector

What industry is Artiva Biotherapeutics Common Stock in?

Artiva Biotherapeutics Common Stock is in the Biotechnology industry

What country is Artiva Biotherapeutics Common Stock from?

Artiva Biotherapeutics Common Stock is headquartered in United States

What is Artiva Biotherapeutics Common Stock website?

https://www.artivabio.com

Is Artiva Biotherapeutics Common Stock in the S&P 500?

No, Artiva Biotherapeutics Common Stock is not included in the S&P 500 index

Is Artiva Biotherapeutics Common Stock in the NASDAQ 100?

No, Artiva Biotherapeutics Common Stock is not included in the NASDAQ 100 index

Is Artiva Biotherapeutics Common Stock in the Dow Jones?

No, Artiva Biotherapeutics Common Stock is not included in the Dow Jones index

When was Artiva Biotherapeutics Common Stock the previous earnings report?

No data

When does Artiva Biotherapeutics Common Stock earnings report?

The next expected earnings date for Artiva Biotherapeutics Common Stock is 29 November 2024